Interesting ImagesBRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA TherapyAhmadzadehfar, Hojjat MD, MSc*; Gaertner, Florian MD*; Lossin, Philipp S. MD†; Schwarz, Bettina MD*; Essler, Markus MD*Author Information From the *Department of Nuclear Medicine, University Hospital Bonn; and †Urological Center Bonn-Rhein-Sieg, Bonn, Germany. Received for publication March 27, 2018; revision accepted April 7, 2018. Conflicts of interest and sources of funding: none declared. Correspondence to: Hojjat Ahmadzadehfar, MD, MSc, Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany. E-mail: [email protected]. Clinical Nuclear Medicine: August 2018 - Volume 43 - Issue 8 - p 609-610 doi: 10.1097/RLU.0000000000002141 Buy Metrics Abstract We present the case of a 66-year-old man with castration-resistant prostate cancer, with an increasing prostate-specific antigen level, and a progressive disease during 177Lu-PSMA radionuclide therapy. Because the patient had a BRCA2 mutation, poly-ADP ribose polymerase inhibitor therapy was started. The patient showed a dramatic subjective and biological response to this therapy with a progression-free survival of 5 months. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.